Anthony D’Amico has been advocating breaking up the intermediate-risk category into “favorable” and “unfavorable,” and now offers yet another circumstance where the optimal treatment is different for each of the two groups, this time with brachytherapy. First, let’s get clear about his definitions. He starts with the current NCCN definition of intermediate risk: Clinical stage […]![]()
